Business Wire

Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion ...

WASHINGTON--(BUSINESS WIRE)--Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of the DynamX ...
Business Wire

EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared ...

PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of breakthrough cardiovascular technologies, today announced that the large international randomized BIOADAPTOR RCT trial of the company’s DynamX ® ...
MarketWatch

EuroPCR 2024: Primary Outcomes from PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical's Hertz Contact Intravascular Lithotripsy System for Calcium ...

The MarketWatch News Department was not involved in the creation of this content. --Primary safety and effectiveness endpoints were met with 98% clinical success rate and 100% angiographic success in ...